Tag: taylor gavinchuk
-
![The top 10 most cashed up psychedelics companies right now]()
The top 10 most cashed up psychedelics companies right now
“In business, cash is oxygen” – Gary Vaynerchuk Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes hundreds of millions of dollars. And that’s only part of the picture. According to Tufts Center for the Study of Drug Development, bringing a new FDA-approved drug…
-
![Gavinchuk: I’m not seeing enough nerdy data talk within the psychedelics space]()
Gavinchuk: I’m not seeing enough nerdy data talk within the psychedelics space
Forget weed crypto First off, most all of those crypto/cannabis hybrid deals were super cringe, and I never saw the point of combining the two, at least not at the scale at which it happened. But psychedelics is a different beast, and tech integrations make a lot more sense than they did with cannabis. It…
-
![Filament Health (FH.NE) is experimenting with mushrooms and compounds far beyond just psilocybin]()
Filament Health (FH.NE) is experimenting with mushrooms and compounds far beyond just psilocybin
Mushroom enthusiasts Filament Health (FH.NE) is looking at mushroom compounds far beyond just psilocybin as the company is run by actual mushroom enthusiasts with access to a lot of tools. Filament has the capabilities to experiment and come up with interesting new compounds, extraction methods, and potential future products that probably go far beyond whatever…
-
![Bruce is on the loose again after Red Light Holland (TRIP.CN) & Creso Pharma (CPH.AX) merger]()
Bruce is on the loose again after Red Light Holland (TRIP.CN) & Creso Pharma (CPH.AX) merger
Everyone who went near a cannabis stock has probably seen or heard of Bruce Linton. He was a charismatic guy who rarely wore more than a t-shirt and jeans. Linton led the Canopy (CGC.Q) through 16 rounds of financing, 31 acquisitions, and $6 billion of capital raises, including a $5 billion investment by Fortune 500…
-
![How to research stocks if you’re not an analyst but still want to go deep]()
How to research stocks if you’re not an analyst but still want to go deep
The land beyond price targets Price targets are an animal I’ve never really taken seriously. This artificially created number gets taken as a realistic goal for many investors, which I guess has value, but price targets are often backed in more ways than one from the funds/investment banks like Cannacord or Eight Capital who put…
-
![Is it weird to talk about suicide, addiction and PTSD in the same breath as stonks and tendies?]()
Is it weird to talk about suicide, addiction and PTSD in the same breath as stonks and tendies?
“Suicide Opportunity” I can’t remember what company it was, maybe MindMed, but one of their early pitch decks had a page titled ‘Suicide Opportunity’. Yesterday I wrote an article outlining how Seelos Therapeutics was targetting suicide with ketamine-based treatments and it reminded me for a moment of that pitch deck. To note, Seelos didn’t word…
-
![Mind Cure (MCUR.C) has pivoted a few times, but may finally be onto something with its focus on tech]()
Mind Cure (MCUR.C) has pivoted a few times, but may finally be onto something with its focus on tech
Multiple pivots Mind Cure (MCUR.C) began as a mushroom nootropic deal that has since shifted to ibogaine production and the development digital platforms. The company has been able to raise a considerable amount of cash while having its hands in several different buckets, bringing in $23 million CAD on a bought deal back in February. Mind…
-
![Bright Minds Biosciences (DRUG.C) is actually really tight]()
Bright Minds Biosciences (DRUG.C) is actually really tight
Serotonin over psychedelics Bright Minds Biosciences (DRUG.C) isn’t banking on recreational psychedelics being relevant any time soon, they aren’t selling mushroom powder, and don’t own any ketamine clinics. Rather, they are developing novel therapeutics to improve the lives of people with severe and life-altering diseases with a focus on 5-HT (serotonin) medicines. The company does…
-
![I am anecdotal evidence for Cybin’s (CYBN.NE) plan to target alcoholism with mushrooms]()
I am anecdotal evidence for Cybin’s (CYBN.NE) plan to target alcoholism with mushrooms
Last week Cybin (CYBN.NE) announced it was targetting alcoholism with its novel psychedelic compound CYB003. Another EG staffer wrote a piece last Monday outlining the details of the plan, but I’m going full editorial for this one as I have some experience with the topic. Through a series of psychedelic trips in my teen years,…
